Inspirational biologics

Waikoloa, Hawaii - Psoriatic patients responding to efalizumab (Raptiva, Genentech Inc. and Xoma Ltd.) biologic medication are happy with the results after an extended period of continuous treatment.

Related Videos

View All

Related Content

The Weekly Roundup: January 16-20

January 20th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Drug Price Hikes Already Found in 2023

January 12th 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

Positive Topline Results Announced for Oral Orismilast for Treatment of Psoriasis

January 9th 2023

The Weekly Roundup: January 2-6

January 6th 2023

The Weekly Roundup: January 16-20

January 20th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Drug Price Hikes Already Found in 2023

January 12th 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

Positive Topline Results Announced for Oral Orismilast for Treatment of Psoriasis

January 9th 2023

The Weekly Roundup: January 2-6

January 6th 2023

The Weekly Roundup: January 16-20

January 20th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Drug Price Hikes Already Found in 2023

January 12th 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

Positive Topline Results Announced for Oral Orismilast for Treatment of Psoriasis

January 9th 2023

The Weekly Roundup: January 2-6

January 6th 2023

Related Content

The Weekly Roundup: January 16-20

Articles

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

Podcasts

Drug Price Hikes Already Found in 2023

Articles

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

Podcasts

Positive Topline Results Announced for Oral Orismilast for Treatment of Psoriasis

Articles

The Weekly Roundup: January 2-6

Articles